AU3252693A - Biochemical deactivation of RNA viruses - Google Patents
Biochemical deactivation of RNA viruses Download PDFInfo
- Publication number
- AU3252693A AU3252693A AU32526/93A AU3252693A AU3252693A AU 3252693 A AU3252693 A AU 3252693A AU 32526/93 A AU32526/93 A AU 32526/93A AU 3252693 A AU3252693 A AU 3252693A AU 3252693 A AU3252693 A AU 3252693A
- Authority
- AU
- Australia
- Prior art keywords
- rna
- viruses
- agents
- deactivation
- biochemical
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 241001493065 dsRNA viruses Species 0.000 title claims description 28
- 230000009849 deactivation Effects 0.000 title claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 30
- 102000006382 Ribonucleases Human genes 0.000 claims description 18
- 108010083644 Ribonucleases Proteins 0.000 claims description 18
- 239000003599 detergent Substances 0.000 claims description 13
- 241001465754 Metazoa Species 0.000 claims description 9
- 208000015181 infectious disease Diseases 0.000 claims description 6
- 238000004140 cleaning Methods 0.000 claims description 5
- 238000004659 sterilization and disinfection Methods 0.000 claims description 4
- 239000011248 coating agent Substances 0.000 claims description 3
- 238000000576 coating method Methods 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 241000450599 DNA viruses Species 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 241000700605 Viruses Species 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 241000196324 Embryophyta Species 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 208000030507 AIDS Diseases 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 210000004877 mucosa Anatomy 0.000 description 3
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 3
- 241000709661 Enterovirus Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- 201000009906 Meningitis Diseases 0.000 description 2
- 241000702244 Orthoreovirus Species 0.000 description 2
- 208000000474 Poliomyelitis Diseases 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 230000002924 anti-infective effect Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 206010014599 encephalitis Diseases 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 239000011241 protective layer Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 102100035526 B melanoma antigen 1 Human genes 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- -1 Bromo- Chemical class 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- 208000000655 Distemper Diseases 0.000 description 1
- 241001466953 Echovirus Species 0.000 description 1
- 241000710188 Encephalomyocarditis virus Species 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 208000000832 Equine Encephalomyelitis Diseases 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 241000710198 Foot-and-mouth disease virus Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 101000874316 Homo sapiens B melanoma antigen 1 Proteins 0.000 description 1
- 241000598436 Human T-cell lymphotropic virus Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000726306 Irus Species 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 241000713869 Moloney murine leukemia virus Species 0.000 description 1
- 241000713333 Mouse mammary tumor virus Species 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000714177 Murine leukemia virus Species 0.000 description 1
- 108020002230 Pancreatic Ribonuclease Proteins 0.000 description 1
- 102000005891 Pancreatic ribonuclease Human genes 0.000 description 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
- 241000709664 Picornaviridae Species 0.000 description 1
- 208000006257 Rinderpest Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 208000010094 Visna Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229960005475 antiinfective agent Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000003836 bluetongue Diseases 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 208000014058 canine distemper Diseases 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 230000002498 deadly effect Effects 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 201000002491 encephalomyelitis Diseases 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 208000031169 hemorrhagic disease Diseases 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 201000011475 meningoencephalitis Diseases 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 239000011814 protection agent Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
- C11D3/16—Organic compounds
- C11D3/38—Products with no well-defined composition, e.g. natural products
- C11D3/386—Preparations containing enzymes, e.g. protease or amylase
- C11D3/38636—Preparations containing enzymes, e.g. protease or amylase containing enzymes other than protease, amylase, lipase, cellulase, oxidase or reductase
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N63/00—Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates
- A01N63/50—Isolated enzymes; Isolated proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/66—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/005—Antimicrobial preparations
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
- C11D3/48—Medical, disinfecting agents, disinfecting, antibacterial, germicidal or antimicrobial compositions
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Plant Pathology (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Pest Control & Pesticides (AREA)
- Agronomy & Crop Science (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dentistry (AREA)
- Environmental Sciences (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Dermatology (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Detergent Compositions (AREA)
- Cosmetics (AREA)
Description
oUII-IIIIo..aI UdLLuVdLIUn u1 mXtim-viruses wiLn agents KaLu as anti-inrectives. 1 inventor and applicant: Dr. Urs V. Wirth; Sonnsyterain, CH- 6048 Horw, Switzerland. Priority date: 23rd June 1992 applied at BAGE in CH; PCT-application: 31st december 1992 at WIPO. Abstract: Ribonucleases (RNases) are highly active, easily used and extremely stable enzymes. Together with detergents, RNases deactivate and destroy irreversibly RNA-viruses. Agents containing RNase(s) and detergents are therefore suitable for disinfecting instruments, clothing and surfaces from contaminating RNA-viruses. Special application forms for coating the skin surfaces of human beings, animals or plants reduce the risk of infection from RNA-viruses. Agents with RNases and detergents, possibly combined with other substances, may be regarded as "anti infectives against RNA viruses (= aiRV)". DESCRIPTION: Ribonucleases (RNases) are extremly stable enzymes and highly active under a variety of assay conditions. RNases inactivate in conjunction with tensides (= detergents ) RNA-Viruses fast and irreversibly, thus this mixture can be designated as anti-infective against RNA-V iruses (aiRVi). AiRVi- mixtures containing RNases and detergents will be called below agents R&D. Agents R&D can be combined with different classical compounds (theoretically in all possible physical states and mixtures) and used for cleaning, disinfection and body care. In addition agents R&D might be combined with other substances and used as new optimized reagents with new formulations as well. Agents R&D are well suited to disinfect objects, such as tools or clothing, contaminated with RNA-viruses. Agents R&D applied to objects and especially to skin surfaces inclusive mucosa are suited to protect humans and/or animals against virulent RNA-viruses. Agents R&D can be used as well for plant protection against RNA-virus diseases. Agents R&D, if necessary combined with other compounds can be used for prevention of diseases caused by RNA-viruses. a) Examples and importance of RNA-viruses: RNA -viruses have as genetic material ribonucleic-acid ( RNA ) either alone or at least as important part: al) Among RNA-viruses are a large number of infectious agents of serious and frequently deadly diseases of mankind and animals: (Source: - : E. Wiesmann, Med. Mikrobiologie, Thieme-Verlag,1974; +: References on request) - Picornaviruses: -- Enteroviruses: -- Poliomyelitis Viruses: e.g. polio --- Coxsackieviren: e.g.. meningitis --- ECHO viruses: e.g. . meningitis & meningoencephalitis -- Rhinoviruses: e.g. common cold - Encephalomyocarditisviruses: - foot and mouth disease virus: - Reoviruses: e.g. Bluetongue, epizootic hemorrhagic disease & equine encephalitis - Arboviruses: e.g. encephalitis or encephalomyelitis - Myxoviruses: - Ortho-Myxoviruses: e.g.. Influenzaviruses -- Para-Myxoviruses.: e.g.. parainfluenza, mumps - Myxosimilar Viruses: e.g.. measles, rubella, canine distemper, rinderpest, hog cholera + certain Hepatitisviruses: e.g. inflammation and tumors of the liver + retroviruses: e.g. RNA-tumorviruses ++ RSV: e.g.. chicken sarcoma, leucosis, MMLV: murine leukemia virus, MMTV: murine mammary tumor virus ++ lentiviruses: e.g. : visna (animals); HTLV (human) P atent a: CH-01-957/92-3 -> PCT/CH92/00249 & WO 94/00016 (U.V.Wirth,1994-l) Biochemical deactivation of KNA-Viruses with agents K&U as anti-inTectives. 2 +++ HTLVIIl = HIV = LAV: (main-) cause for AIDS (acquired immune deficiency) of mankind and similar viruses of animals: e.g. : SIV (simian), BIV (bovine), FIV (feline) a2) RNA-Viruses causing diseases in plants: (source: F. Sch6nbeck, Pflanzenkrankheiten, Teubner, 1979) - leaf-Mosaic-virus: Como-, Tobamo-, Bromo-, and other groups. - Rhabdoviruses: - Reoviruses: b) Properties of RNases (e.g. RNase A): - Stability: heat stable (full activity even after boiling!) and stable under dry or wet conditions. - Activity: only slightly modified activity by pH (5-8 optimal) or by changes of salt concentrations (0.3 Mol/1 NaCI optimum) or by detergents (e.g. SLS= Sodium Lauryl Sulphate). c) Effects of RNase and detergents on RNA-Viruses: - RNA-Viruses are built from their genetic material RNA and a protecting shell (=capsid) made from proteins. Certain RNA-Viruses have in addition an outer membrane, consisting of lipids and proteins. -Agents R&D contain RNases and detergents, if necessary with additives for stabilization and/or enhancement of activity & stability and eventually combined with different classical compounds. As anti-infectiva against RNA-Viruses (aiRVi) such agents cause deactivation of RNA-viruses: Detergents (= tensides = amphiphilic substances) dissolve the membrane and break the capside, then RNases hydrolyze (destroy) the genetic material (RNA) of the viruses, these steps result in a complete destruction of the RNA-viruses. Detergents alone can reduce the infection potential of some RNA-viruses to a certain degree. Thus in addition to limit specific large scale uptake of viruses by host cells by detergents, every possibility of viral multiplication in host cells or their debris is completely eliminated. The novel additional destruction of the genetic material RNA by the agents R&D for complete inactivation might be relevant, because it has been recently shown, that e.g. polio virus multiplies its RNA in intact or even in lysed cells (Science News, Vol.140, p.390, 1991). d) Agents R&D: Agents R&D can be combined together with different, classical substances for cleaning, disinfection and body care or can be created as new optimized reagents in different combinations with new formulations: - For cleaning and disinfection one needs at least a RNase (e.g. RNaseA) and one detergent (e.g. Sodium Lauryl Sulfate). Basic research has shown, that RNases under extremely varying conditions effectively hydrolyze. - For protection against infections, agents R&D might be used in all body care products such as: body lotions, cremes, hair-shampoos, shower-gels, powders, mouth hygienic solutions, eye-care liquids, genital solutions, .... Depending on the products and their application, these agents act within a short time to deactivate RNA-Viruses (disinfectant) or deliver a long term deactivation potential against RNA-Viruses (e.g. durable protection film). For a desired long term protective effect, one needs agents which establish a resistent layer (protection film) on the surface (tools, clothes, skin, mucosa). Such agents, based on gels, oils or wax are in part already patented and are used in practice. e) Use of agents R&D: - In plant protection to disinfect contaminated tools and to prevent disease by a resistant protective layer (wax or oil) together with plant protection agents. - For animals to disinfect tools, living areas and animals themselves. - For humans to clean and disinfect contaminated tools, surfaces, clothes and even body surface (skin and mucosa). Especially high risk places such as living or resting rooms of RNA virus excreting persons; e.g. in hospitals, laboratories, consulting rooms, ... possibly schools, sport facilities, hotels. Furthermore these agents can be used for general prevention against RNA viruses. People with contact to infected persons or their contaminated belongings have a relative higher risk for infection (e.g. physicians, nurses, cleaning personnel,...) and could protect themselves with protective layers. Considering the AIDS causing HIV RNA-viruses, protection of high risk groups is extremely urgent. Agents with RNases could be added to classic mechanical and chemical contraceptiva. Condoms and femidoms as so far best indicated and most propagated way to protect against infection could be treated with agents containing agents R&D as coating film or agents R&D Patent: CH-01-957/92-3 -> PCT/CH92/00249 & WO 94/00016 (U.V.Wirth,1994-l)
Claims (4)
1. Agent for biochemical deactivation of RNA-viruses, consisting of ribonuclease(-s) = RNase(-s) together with at least one detergent.
2. Agent of claim 1 wherein it is used for cleaning, disinfection, body care or coating surfaces.
3. Agent of claim 1 wherein it is used for protection of mankind, animals and/or plants against infection by RNA-viruses. additional claim legalized by WIPO (4th October 1993):
4. Agent of claim 1 wherein it is used for targeted and local therapy of infectious diseases by RNA and DNA viruses or localised tumors of mankind and animals. Patent: CH-01-957/92-3 -> PCT/CH92/00249 & WO 94/00016 (U.V.Wirth,1994-l)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH1957/92A CH682541A5 (en) | 1992-06-23 | 1992-06-23 | Biochemical Inactivation of RNA viruses. |
| CH1957/92 | 1992-06-23 | ||
| PCT/CH1992/000249 WO1994000016A1 (en) | 1992-06-23 | 1992-12-31 | Biochemical deactivation of rna viruses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU3252693A true AU3252693A (en) | 1994-01-24 |
Family
ID=4222554
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU32526/93A Abandoned AU3252693A (en) | 1992-06-23 | 1992-12-31 | Biochemical deactivation of RNA viruses |
Country Status (4)
| Country | Link |
|---|---|
| AU (1) | AU3252693A (en) |
| CA (1) | CA2116661A1 (en) |
| CH (1) | CH682541A5 (en) |
| WO (1) | WO1994000016A1 (en) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6017046A (en) * | 1998-01-21 | 2000-01-25 | Markovic; Vladimir | Wheelchair apparatus |
| KR100454594B1 (en) * | 2002-07-22 | 2004-11-03 | 배흥규 | Rice cutlet and process for manufacturing thereof |
| DE102004001590B4 (en) * | 2004-01-09 | 2012-12-06 | Gerhard Knapp | Use of an active substance and a combination of active substances for inhibiting mite faeces and / or mold spores and / or plant pollen and spores and / or for denaturing the keratin of animal hair |
| MX394626B (en) | 2014-07-31 | 2025-03-24 | Kimberly Clark Co | ALCOHOL-BASED NON-STICK COMPOSITION. |
| GB2547341B (en) | 2014-07-31 | 2022-08-17 | Kimberly Clark Co | Anti-adherent composition |
| AU2015297023B2 (en) | 2014-07-31 | 2019-11-07 | Kimberly-Clark Worldwide, Inc. | Anti-adherent composition |
| WO2016160006A1 (en) | 2015-04-01 | 2016-10-06 | Kimberly-Clark Worldwide, Inc. | Fibrous substrate for capture of gram negative bacteria |
| MX2018008569A (en) | 2016-01-28 | 2018-08-16 | Kimberly Clark Co | Anti-adherent composition against dna viruses and method of inhibiting the adherence of dna viruses to a surface. |
| AU2016408394B2 (en) | 2016-05-26 | 2021-11-11 | Kimberly-Clark Worldwide, Inc. | Anti-adherent compositions and methods of inhibiting the adherence of microbes to a surface |
| WO2020070014A1 (en) * | 2018-10-02 | 2020-04-09 | Novozymes A/S | Cleaning composition comprising anionic surfactant and a polypeptide having rnase activity |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR6614M (en) * | 1967-03-16 | 1969-01-13 | ||
| US3849254A (en) * | 1973-05-31 | 1974-11-19 | Univ Virginia | Process for effecting enzymatic reactions in aerosols |
| IL78703A (en) * | 1985-05-10 | 1993-02-21 | Benzon Alfred | Method of producing extracellular enzymes, the enzymes produced thereby and compositions containing them; a hybrid plasmid and a dna fragment comprising dna encoding the enzymes; a microorganism harbouring the plasmid; and a method for removing nucleic acids from biological materials |
| HU204710B (en) * | 1988-05-26 | 1992-02-28 | Nika Health Products Inc | Process for producing pharmaceutical compositions having antiviral and antibacterial effect |
| DE3939771A1 (en) * | 1989-12-01 | 1991-06-06 | Behringwerke Ag | PROCESS FOR THE BIOLOGICAL INACTIVATION OF NUCLEIC ACIDS |
| DE4016483A1 (en) * | 1990-05-22 | 1991-11-28 | Klinger & Co Dr | Treatment against phytopathogenic viruses - using nuclease(s) aq. soln. for plants, fungi and fungal spores |
| DE4024530A1 (en) * | 1990-08-02 | 1992-02-06 | Klinger & Co Dr | Control of viral disease using bovine pancreatic nuclease(s) - for treatment of e.g. rabies, herpes, Epstein-Barr virus and cow-pox |
-
1992
- 1992-06-23 CH CH1957/92A patent/CH682541A5/en not_active IP Right Cessation
- 1992-12-31 CA CA002116661A patent/CA2116661A1/en not_active Abandoned
- 1992-12-31 AU AU32526/93A patent/AU3252693A/en not_active Abandoned
- 1992-12-31 WO PCT/CH1992/000249 patent/WO1994000016A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| CA2116661A1 (en) | 1994-01-06 |
| WO1994000016A1 (en) | 1994-01-06 |
| CH682541A5 (en) | 1993-10-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4797420A (en) | Disinfectant formulation and method of use | |
| BR9810745A (en) | Benzimidazole derivatives | |
| AU3252693A (en) | Biochemical deactivation of RNA viruses | |
| BG100455A (en) | Hiv protease inhibitors | |
| JP2006519841A (en) | Surface disinfecting composition with improved antibacterial performance | |
| Dastider et al. | Hand sanitizers bid farewell to germs on surface area of hands | |
| EP0457805A1 (en) | Biodegradable disinfectant | |
| EP0190797A2 (en) | Method for killing viruses and composition therefor | |
| Verma et al. | Effectiveness of mouthwash against viruses: 2020 perspective. A systematic review | |
| ATE179164T1 (en) | HIV PROTEASE INHIBITORS | |
| JP3159704B2 (en) | Azo derivatives and use of these derivatives as drugs and anti-AIDS agents | |
| US20090042870A1 (en) | Antimicrobial Composition | |
| TR200101841T2 (en) | The use of bisphosphonates to prevent infections and treat infections | |
| JP2004352642A (en) | Prophylactic against viral infectious disease | |
| Miller et al. | Formation of Invisible, Non-perceptible Films on Hands by Cationic Soaps. | |
| ATE309803T1 (en) | SPHINGOMYELINASE INHIBITORS AS ACTIVE INGREDIENTS WITH ANTIAPOPTOTIC AND ANTISEPTIC EFFECTS | |
| Dorgham et al. | Disinfectants and Skin Antiseptics for Safe prophylaxis against COVID-19, Review of Literature. | |
| US20230151302A1 (en) | Cationic surfactants, in particular ethyl lauroyl arginate LAE, for treating or preventing infections and contaminations with Coronavirus | |
| Allen et al. | Efficacy of 9-β-d-Arabinofuranosylhypoxanthine 5′-Monophosphate in Therapy of Equine Abortion Virus-Induced Hepatitis in Hamsters | |
| Babu et al. | Data science: a survey on the statistical analysis of the latest outbreak of the 2019 pandemic novel coronavirus disease (COVID-19) using ANOVA | |
| Friedland | In Vitro Antiviral Activity of a Peptide-Nucleic Acid Solution* Against the Human immunodeficiency Virus and influenza A Virus | |
| JPH05505390A (en) | Active agents against retroviruses, compositions containing the active agents, and uses thereof | |
| Raja et al. | Pre-eminence and comparative analysis of skin and surface disinfectants: A systematic review to pave the way for SARS-CoV-2 prevention | |
| JPH01502113A (en) | Methods of prevention and compositions therefor | |
| Ndukuba et al. | Personal Hygiene Protocols in Infectious Disease Control-Lessons from the Spread of SARS-CoV-2 |